All Search Results
-
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC)
-
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Social Genomic Mechanisms of Health Disparities among Adolescent and Young Adult (AYA) Survivors of Hodgkin and Non-Hodgkin Lymphoma
-
NICU Development Clinic
At the NICU Development Clinic of Orlando Health Arnold Palmer Hospital for Children, we care about the long-term success of your baby and are here to help keep them on track for a healthy and happy childhood. That’s why our relationship doesn’t end when your baby leaves the neonatal intensive care unit (NICU).
-
Orlando Health — Health Central Hospital ER
Welcome to Health Central Hospital's Emergency Department.
-
Mothers and Babies with Special Needs
Hospitalized as part of a high-risk pregnancy? We’re here for you. With our supportive and comprehensive care, we can help ease your stress and help you feel safe and cared for.
-
Vascular Anomalies Clinic
Comprehensive evaluation, diagnosis, management and care coordination for those affected with vascular lesions.
-
About Us
Orlando Health Arnold Palmer Hospital for Children and Orlando Health Winnie Palmer Hospital for Women & Babies is the largest facility dedicated to children and women in the United States. We have many strengths that make us a leader in women's healthcare. Among them:
-
Teen battles rare condition and copes with art, mother becomes advocate to build awareness
See how this family learns to live with pulmonary hypertension and how they are helping others.
-
Room Sharing vs. Bed Sharing
The differences between these two sleeping arrangements can mean life or death for your baby. Dr. Rachel Prete, Pediatrician at Arnold Palmer Hospital for Children answers questions about the differences of each, their pros and cons and tips for new parents considering each approach.
-
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥1 to <31 Years Old With First Relapse
